Searched for
DASATINIB GENERIC LAUNCH
Biocon plans $150-million capex in two yearsBiocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 mi...10 May, 2025, 08.31 PM IST- Biocon Q4 results: Net profit surges 153% at Rs 344 croreBiocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore. The company's bi...09 May, 2025, 08.43 AM IST
- Aurobindo Pharma arm gets USFDA nod for generic blood cancer drugAurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd, has secured USFDA approval to produce and sell generic Dasatinib tablets, use...23 Apr, 2025, 03.04 PM IST
- Dr Reddy's Laboratories planning mergers and acquisitions to climb up ladderIndia contributed about a fifth or ₹4,196 crore of the company's overall sales of ₹21,439 crore in 2021-22, but domestic business has clock...24 Jun, 2022, 03.54 PM IST
- Shilpa Medicare launches cancer drug at monthly therapy cost of Rs 6,440The drug substance patent on Dasatinib was owned by Bristol-Myers-Squibb and had expired on 12 April 12, 2020. The current monthly therapy ...24 Apr, 2020, 10.56 AM IST
- Market Movers: L&T, Lupin, DRL gain; HDFC twins key drag; 50 stocks enter ‘buy’ zoneHDFC twins and Reliance Industries were among the biggest drags, but a jump in L&T after three ‘large’ order wins cushion the fall to some ...13 Apr, 2020, 05.51 PM IST
- Two generics makers end battle to copy drugs amid patent debateBoth companies, BDR Pharma and Lee Pharma, had been seeking so-called compulsory licenses that override patents and allow generics firms in...12 Apr, 2016, 05.42 PM IST
- MNCs deprive India of vital drugs despite getting monopoly rightsJapanese firm Otsuka Pharmaceuticals, Myers-Squibb, Novartis are deferring launch of medicines critical for treatment of serious non-commun...30 Nov, 2014, 10.26 AM IST
- Cipla asks government to revoke five patents held by NovartisCipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...30 Oct, 2014, 11.35 AM IST
- Japan's Eisai to launch breast cancer drug in IndiaJapan's Eisai Pharma is slated to launch in India its novel anti-cancer drug Eribulin, sold under the brand name of Halaven.06 Nov, 2013, 03.15 AM IST
- BDR Pharma seeks cancer drug licenceBDR Pharma has filed an application with the Mumbai Patent Office, seeking compulsory licence to market a crucial cancer drug, dasatinib19 Mar, 2013, 10.52 AM IST
- Delhi High Court gives Natco Pharma a week to respond to Bristol-Myers Squibb contempt chargesDelhi HC has given Natco Pharma a week's time to respond to the contempt charges slapped by American firm Bristol-Myers Squibb (BMS).04 Aug, 2012, 04.52 PM IST
- Natco Pharma, Bristol-Myers Squibb face off in Court over sale of dasatinib cloneHyderabad-based Natco says it has not reneged on its undertaking as its version of the drug is different and does not infringe upon the pat...01 Aug, 2012, 05.22 AM IST
- Natco Pharma begins sales of Bristol Myers' cancer drug DasatinibHyderabad-based generic drugmaker Natco Pharma has started selling copies of global pharma major Bristol Myers Squibb's cancer drug Dasatin...13 Jul, 2012, 02.35 AM IST
- DCGI’s plan on patent linkage gets HC boosterThe Delhi High Court (HC) has directed the drug controller general of India (DCGI) not to give marketing or manufacturing permission to gen...08 Jan, 2009, 12.17 AM IST
- Delhi HC directs DCGI not to permit generic drugmakers for drugs already patentedThe Delhi HC has directed the drug controller general of India to not give marketing or manufacturing permission to generic drug makers for...07 Jan, 2009, 07.45 PM IST
- Delhi HC debarred Generic durgmakers from marketingThe Delhi High Court (HC) has asked the drug controller general of India (DCGI) not to give marketing or manufacturing permission to generi...07 Jan, 2009, 01.38 PM IST
Load More
